145349-74-2

Upstream product

• 79887-10-8 1-ethynyl-4-(n-pentyl)benzene 
• 540-37-4 p-aminoiodobenzene 
• 14221-01-3 tetrakis(triphenylphosphine) palladium⁽⁰⁾ 

Relevant academic research and scientific papers

Tolane liquid crystals with piperidine, 3,3,4,4,5,5-hexafluoropiperidine as end group: Synthesis and properties

A series of new tolane liquid crystals with piperidine and 3,3,4,4,5,5-hexafluoropiperidine as their terminal groups were synthesized via Sonagashira reaction by using Pd(PPh3)2Cl2/CuI as the catalyst. Their structures were modified by varying the terminal N-heterocycles and/or the length of the alkyl/alkoxy chains on the benzene ring. Most of these new compounds exhibit Smectic B or G mesophases, good thermal stabilities and high clearing points. The molecule C2H5O6F with 3,3,4,4,5,5-hexafluoropiperidine as the end group has a broader HOMO-LUMO energy gap and higher oxidation potential than piperidine derivative C2H5O6H. The result indicates that the oxidation resistance of the tolane liquid crystals was improved by introducing the terminal fluorinated piperidine.

INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER

A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Synthesis, mesomorphic behaviour and optical anisotropy of some novel materials for nematic mixtures of high birefringence

Structural moieties including core units (such as phenyl, naphthyl and thiophenyl), linking groups (such as ethynyl), terminal substituents (such as cyano, isothiocyanato and fluoro), and lateral fluoro substituents have been incorporated into novel mater

Anisotropic organic compounds

STR1 The invention describes liquid crystalline compounds or formula (I), where A, D and G are independently selected from phenyl, thiophene, hydrogenated phenyl, chlorinated phenyl and fluorinated phenyl, B and E are independently selected from a single bond C= C. C C.C00, azoxy and diazo, k and m are independently selected from 1 and 0, such that m+n is 1 or 2, and R1 and R2 are independently selected from R, R0, alkynyl, thioalkyl, hydrogen, CN, NCS and SCN; provided that at least one of R1 and R2 is selected from CN, NCS and SCN and that at least one of A, D and G is phenyl; and excluding where at least one of R1 and R2 is independently selected as CN and one of A, D or G is not thiophene, and where m is 0, A, and D are phenyl, B is a single bond and only one of R1 or R2 is NCS. Also described are compounds suitable for inclusion in a device utilizing pretransitional characteristics of liquid crystalline materials in the isotropic phase, of general formula (II) where J and Y are independently selected from phenyl, thiophene, hydrogenated phenyl, chlorinated phenyl and fluorinated phenyl, X is selected from C= C. C C.COO azoxy and diazo, k is 1 or 0 and R3 and R4 are independently selected from R, RO, alkynyl, thioalkyl, hydrogen, CN, NCS and SCN; provided that at least one of R3 and R4 is selected from CN, NCS and SCN and that at least one of J and Y is phenyl.